As President of the Templeton World Charity Foundation, Andrew Serazin, Ph.D., is responsible for all aspects of the foundation’s philanthropic activities as well as effective stewardship of its financial resources. As a researcher, entrepreneur, and executive, Dr. Serazin has worked to bring scientific and technical advances to bear on some of the world’s most pressing challenges.
From 2006 to 2012, Dr. Serazin served as Senior Program Officer in Global Health Discovery & Translational Science at the Bill & Melinda Gates Foundation. At the Gates foundation, he was responsible for bringing new products, scientific approaches, and technologies to nutrition and human development. He founded and led Grand Challenges Explorations, an early-stage medical research fund that has attracted ideas from 60,000 scientists in over 100 countries and has resulted in over 1000 projects.
As a complement to philanthropic endeavors, Dr. Serazin is an entrepreneur. He was founding CEO of Matatu Inc, a venture-backed biotechnology company dedicated to applying insights about microbiome and nutrition to health. He has also worked as an advisor to Mars Inc, one of the world’s largest food companies, on programs to harness market-oriented efforts to improving the quality and diversity of food choices for consumers in Africa and Asia.
Earlier in his career Dr. Serazin was Departmental Lecturer in the Zoology Department at University of Oxford conducting infectious disease research and teaching courses on the biology of disease. He received his doctorate for his work on developing new genomic technologies to accelerate design of new drugs and vaccines against malaria from the University of Oxford as a Rhodes Scholar.
Dr. Serazin has also been a member of the College of Science Advisory Council of the University of Notre Dame, where he received his undergraduate degree. His original research has been presented at many international meetings and in leading peer-reviewed journals including Science, the PLoS Medicine, Nature Immunology, and Lancet.